Biotechnology company developing next-generation siRNA therapeutics using liver- and extrahepatic-delivery platforms
Biotechnology company developing next-generation siRNA therapeutics using liver- and extrahepatic-delivery platforms. Its pipeline targets metabolic, cardiovascular, liver, and central nervous system diseases, including obesity, hypertriglyceridemia, ASCVD, hypertension, MASH, epilepsy, and Alzheimer's disease.